1. Introduction
1.1 Business Market Insights Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Market Insights
2.2 Market Attractiveness
3. Research Methodology
3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Hypothesis formulation:
- 3.2.2 Macro-economic factor analysis:
- 3.2.3 Developing base number:
- 3.2.4 Data Triangulation:
- 3.2.5 Country level data:
4. Europe Vaccine Adjuvants Market Landscape
4.1 Market Overview
4.2 Porter's Five Forces Analysis
- 4.2.1 Bargaining Power of Suppliers
- 4.2.2 Bargaining Power of Buyers
- 4.2.3 Threat of New Entrants
- 4.2.4 Competitive Rivalry
- 4.2.5 Threat of Substitutes
4.3 Ecosystem Analysis
- 4.3.1 Raw Material Suppliers
- 4.3.2 Manufacturers
- 4.3.3 Distributors/Suppliers
- 4.3.4 End Users
5. Europe Vaccine Adjuvants Market – Key Market Dynamics
5.1 Growth Drivers
- 5.1.1 Advantages of Vaccine Adjuvants to Favor Market
5.2 Market Opportunities
- 5.2.1 Collaborative Efforts for Vaccine Adjuvants
5.3 Future Trends
- 5.3.1 Product Launches and Developments in Adjuvant Studies
5.4 Impact of Drivers and Restraints
6. Europe Vaccine Adjuvants Market Country Analysis
6.1 Europe Vaccine Adjuvants Market Overview
6.2 Europe Vaccine Adjuvants Market Revenue 2020-2030 (US$ Million)
6.3 Europe Vaccine Adjuvants Market Forecast Analysis
7. Europe Vaccine Adjuvants Market Analysis – by Adjuvant Class
7.1 Mineral Salt Adjuvant
- 7.1.1 Overview
- 7.1.2 Mineral Salt Adjuvant: Europe Vaccine Adjuvants Market – Revenue and Forecast to 2031 (US$ Million)
7.2 Emulsion Adjuvant
- 7.2.1 Overview
- 7.2.2 Emulsion Adjuvant: Europe Vaccine Adjuvants Market – Revenue and Forecast to 2031 (US$ Million)
7.3 Liposome Adjuvant
- 7.3.1 Overview
- 7.3.2 Liposome Adjuvant: Europe Vaccine Adjuvants Market – Revenue and Forecast to 2031 (US$ Million)
8. Europe Vaccine Adjuvants Market Analysis – by Type
8.1 Human Vaccine Adjuvant
- 8.1.1 Overview
- 8.1.2 Human Vaccine Adjuvant: Europe Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
8.2 Veterinary Vaccine Adjuvant
- 8.2.1 Overview
- 8.2.2 Veterinary Vaccine Adjuvant: Europe Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
9. Europe Vaccine Adjuvants Market – Europe (UK, Germany, France, Russia, Italy, Rest of Europe) Analysis
9.1 Europe (UK, Germany, France, Russia, Italy, Rest of Europe)
- 9.1.1 Europe (UK, Germany, France, Russia, Italy, Rest of Europe): Europe Vaccine Adjuvants Market – Revenue
and Forecast to 2030 (US$ Million)
- 9.1.1.1 Europe (UK, Germany, France, Russia, Italy, Rest of Europe):
Europe Vaccine Adjuvants Market Breakdown, by Adjuvant Class
- 9.1.1.2 Europe (UK, Germany, France, Russia, Italy, Rest of Europe):
Europe Vaccine Adjuvants Market Breakdown, by Type
10. Competitive Landscape
10.1 Heat Map Analysis
10.2 Company Positioning and Concentration
11. Europe Vaccine Adjuvants Market Industry Landscape
11.1 Overview
11.2 Mergers and Acquisitions
11.3 Agreements, Collaborations, and Joint Ventures
11.4 New Product Launches
11.5 Expansions and Other Strategic Developments
12. Company Profiles
12.1 SPI Pharma Inc
- 12.1.1 Key Facts
- 12.1.2 Business Description
- 12.1.3 Products and Services
- 12.1.4 Financial Overview
- 12.1.5 SWOT Analysis
- 12.1.6 Key Developments
12.2 GSK Plc
- 12.2.1 Key Facts
- 12.2.2 Business Description
- 12.2.3 Products and Services
- 12.2.4 Financial Overview
- 12.2.5 SWOT Analysis
- 12.2.6 Key Developments
12.3 CSL Ltd
- 12.3.1 Key Facts
- 12.3.2 Business Description
- 12.3.3 Products and Services
- 12.3.4 Financial Overview
- 12.3.5 SWOT Analysis
- 12.3.6 Key Developments
12.4 Seppic SA
- 12.4.1 Key Facts
- 12.4.2 Business Description
- 12.4.3 Products and Services
- 12.4.4 Financial Overview
- 12.4.5 SWOT Analysis
- 12.4.6 Key Developments
12.5 Dynavax Technologies Corp
- 12.5.1 Key Facts
- 12.5.2 Business Description
- 12.5.3 Products and Services
- 12.5.4 Financial Overview
- 12.5.5 SWOT Analysis
- 12.5.6 Key Developments
12.6 InvivoGen SAS
- 12.6.1 Key Facts
- 12.6.2 Business Description
- 12.6.3 Products and Services
- 12.6.4 Financial Overview
- 12.6.5 SWOT Analysis
- 12.6.6 Key Developments
12.7 Croda International Plc
- 12.7.1 Key Facts
- 12.7.2 Business Description
- 12.7.3 Products and Services
- 12.7.4 Financial Overview
- 12.7.5 SWOT Analysis
- 12.7.6 Key Developments
12.8 Novavax Inc
- 12.8.1 Key Facts
- 12.8.2 Business Description
- 12.8.3 Products and Services
- 12.8.4 Financial Overview
- 12.8.5 SWOT Analysis
- 12.8.6 Key Developments
12.9 Phibro Animal Health Corp
- 12.9.1 Key Facts
- 12.9.2 Business Description
- 12.9.3 Products and Services
- 12.9.4 Financial Overview
- 12.9.5 SWOT Analysis
- 12.9.6 Key Developments
13. Appendix
13.1 About Business Market Insights